Volume 19, Number 11—November 2013
Dispatch
Severe Plasmodium vivax Malaria in Pakistan
Table 1
Characteristic |
Frequency (%) |
||
---|---|---|---|
P. vivax |
P. falciparum |
Mixed |
|
Sex | |||
F | 98 (33) | 12 (25) | 6 (46) |
M | 198 (67) | 35 (75) | 7 (54) |
Previously healthy adults | 189 (64) | 30 (64) | 10 (77) |
Concurrent illness | |||
Diabetes | 49 (17) | 4 (9) | 0 |
Ischemic heart disease | 37 (12) | 2 (4) | 3 (23) |
Chronic kidney disease | 10 (3) | 3 (6) | 0 |
Co-existing infection† | 34 (12) | 5 (11) | 0 |
Others‡ | 10 (3) | 5 (11) | 0 |
Total§ | 107 (36) | 17 (36) | 3 (23) |
*n = 356.
†Co-existing infections included dengue fever, urinary tract infection, enteric fever, and hepatitis C, diagnosed by appropriate serologic testing/culture.
‡Other conditions included chronic obstructive pulmonary disease, chronic liver disease, malignancy, and other conditions from the Charlson Comorbidity Index (5).
§Many patients had multiple comorbidities; therefore, the total does not sum the above.
References
- World Health Organization. World malaria report: 2011. Geneva: The Organization; 2011.
- Imwong M, Pukrittayakamee S, Grüner AC, Rénia L, Letourneur F, Looareesuwan S, Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1. Malar J. 2005;4:20 . DOIPubMedGoogle Scholar
- Zakeri S, Bereczky S, Naimi P, Pedro Gil J, Djadid ND, Färnert A, Multiple genotypes of the merozoite surface proteins 1 and 2 in Plasmodium falciparum infections in a hypoendemic area in Iran. Trop Med Int Health. 2005;10:1060–4. DOIPubMedGoogle Scholar
- World Health Organization. Guidelines for the treatment of malaria, 2nd ed. Geneva: The Organization; 2010.
- Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57:1288–94. DOIPubMedGoogle Scholar
- Beg MA, Sani N, Mehraj V, Jafri W, Khan MA, Malik A, Comparative features and outcomes of malaria at a tertiary care hospital in Karachi, Pakistan. Int J Infect Dis. 2008;12:37–42. DOIPubMedGoogle Scholar
- Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis. 2009;22:430–5. DOIPubMedGoogle Scholar
- Douglas NM, Anstey NM, Buffet PA, Poespoprodjo JR, Yeo TW, White NJ, The anaemia of Plasmodium vivax malaria. Malar J. 2012;11:135. DOIPubMedGoogle Scholar
- Sharma A, Khanduri U. How benign is benign tertian malaria? J Vector Borne Dis. 2009;46:141–4 .PubMedGoogle Scholar
- Kochar DK, Das A, Kochar SK, Saxena V, Sirohi P, Garg S, Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India. Am J Trop Med Hyg. 2009;80:194–8 .PubMedGoogle Scholar
- Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis. 2009;9:555–66 . DOIPubMedGoogle Scholar
Page created: October 31, 2013
Page updated: October 31, 2013
Page reviewed: October 31, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.